CO2022010098A2 - Inhibidores de proteínas kras mutantes - Google Patents
Inhibidores de proteínas kras mutantesInfo
- Publication number
- CO2022010098A2 CO2022010098A2 CONC2022/0010098A CO2022010098A CO2022010098A2 CO 2022010098 A2 CO2022010098 A2 CO 2022010098A2 CO 2022010098 A CO2022010098 A CO 2022010098A CO 2022010098 A2 CO2022010098 A2 CO 2022010098A2
- Authority
- CO
- Colombia
- Prior art keywords
- mutant kras
- protein inhibitors
- kras protein
- mutant
- inhibitor
- Prior art date
Links
- 229940121649 protein inhibitor Drugs 0.000 title abstract 2
- 239000012268 protein inhibitor Substances 0.000 title abstract 2
- 101150105104 Kras gene Proteins 0.000 title 1
- 102100030708 GTPase KRas Human genes 0.000 abstract 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
RESUMEN DE LA INVENCIÓN La invención se refiere a un inhibidor de la proteína KRAS mutante mostrado como fórmula (I), una composición que contiene el inhibidor y su uso. (I).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019126687 | 2019-12-19 | ||
| CN2020070885 | 2020-01-08 | ||
| CN2020073723 | 2020-01-22 | ||
| CN2020078565 | 2020-03-10 | ||
| PCT/CN2020/137497 WO2021121367A1 (en) | 2019-12-19 | 2020-12-18 | Kras mutant protein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022010098A2 true CO2022010098A2 (es) | 2022-10-11 |
Family
ID=76478185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0010098A CO2022010098A2 (es) | 2019-12-19 | 2022-07-18 | Inhibidores de proteínas kras mutantes |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11180506B2 (es) |
| EP (1) | EP4077326A4 (es) |
| JP (1) | JP7644517B2 (es) |
| KR (1) | KR20220119088A (es) |
| CN (4) | CN113454083A (es) |
| AU (1) | AU2020404319A1 (es) |
| BR (1) | BR112022011421A2 (es) |
| CA (1) | CA3165238A1 (es) |
| CL (1) | CL2022001670A1 (es) |
| CO (1) | CO2022010098A2 (es) |
| CR (1) | CR20220351A (es) |
| IL (1) | IL293962B2 (es) |
| MX (1) | MX2022007527A (es) |
| PE (1) | PE20230161A1 (es) |
| PH (1) | PH12022551503A1 (es) |
| TW (1) | TWI871397B (es) |
| WO (1) | WO2021121367A1 (es) |
| ZA (2) | ZA202207450B (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110612294B (zh) | 2017-01-31 | 2024-01-16 | 阿尔维纳斯运营股份有限公司 | 人小脑蛋白配体和包含其的双官能化合物 |
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| UA128558C2 (uk) | 2018-07-20 | 2024-08-14 | Ф. Хоффманн-Ля Рош Аг | Сульфонімідамідні сполуки як інгібітори активності інтерлейкіну-1 |
| WO2020055760A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US12336995B2 (en) | 2018-09-10 | 2025-06-24 | Mirati Therapeutics, Inc. | Combination therapies |
| HRP20250059T1 (hr) | 2018-09-10 | 2025-03-28 | Mirati Therapeutics, Inc. | Kombinirane terapije |
| WO2020085493A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| JP2022509724A (ja) | 2018-12-05 | 2022-01-24 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| WO2020156285A1 (zh) * | 2019-01-29 | 2020-08-06 | 博瑞生物医药（苏州）股份有限公司 | 一种苯并吡啶酮杂环化合物及其用途 |
| JP7622043B2 (ja) | 2019-08-29 | 2025-01-27 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| AU2020356455A1 (en) | 2019-09-24 | 2022-04-14 | Mirati Therapeutics, Inc. | Combination therapies |
| PE20221253A1 (es) | 2019-10-28 | 2022-08-16 | Merck Sharp & Dohme | Inhibidores de pequenas moleculas de mutante g12c de kras |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| CN113454083A (zh) * | 2019-12-19 | 2021-09-28 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
| CN115175901B (zh) | 2019-12-19 | 2024-03-22 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| CN115135315B (zh) | 2019-12-20 | 2024-11-26 | 米拉蒂治疗股份有限公司 | Sos1抑制剂 |
| CN114671866A (zh) * | 2020-12-25 | 2022-06-28 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| WO2021249563A1 (zh) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| JP2023540809A (ja) | 2020-09-11 | 2023-09-26 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤の結晶形態 |
| TW202214630A (zh) * | 2020-09-12 | 2022-04-16 | 大陸商成都倍特藥業股份有限公司 | 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用 |
| US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| KR20230142465A (ko) | 2020-12-15 | 2023-10-11 | 미라티 테라퓨틱스, 인크. | 아자퀴나졸린 범-KRas 저해제 |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| IL308193A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors |
| EP4334325A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| CN117295742A (zh) * | 2021-05-12 | 2023-12-26 | 北京加科思新药研发有限公司 | 化合物ⅰ的新形式及它们的应用 |
| CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| CN115894520A (zh) * | 2021-09-23 | 2023-04-04 | 上海和誉生物医药科技有限公司 | 一种大环k-ras g12c抑制剂及其制备方法和在药学上的应用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| US20250282782A1 (en) | 2021-12-17 | 2025-09-11 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| CN116327956B (zh) * | 2022-04-01 | 2025-11-28 | 劲方医药科技(上海)股份有限公司 | 药物组合物、其用途及癌症的治疗方法 |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR102724980B1 (ko) | 2022-09-21 | 2024-10-31 | 한화솔루션 주식회사 | 탠덤 태양전지 및 이의 제조방법 |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途 |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| AU2024243852A1 (en) | 2023-04-07 | 2025-11-06 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202448897A (zh) | 2023-04-14 | 2024-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025036475A1 (en) * | 2023-08-17 | 2025-02-20 | Jacobio Pharmaceuticals Co., Ltd. | A pharmaceutical combination and use thereof |
| WO2025036470A1 (en) * | 2023-08-17 | 2025-02-20 | Jacobio Pharmaceuticals Co., Ltd. | Use of compound a for treating a cancer |
| TW202529768A (zh) | 2023-09-29 | 2025-08-01 | 大陸商德昇濟醫藥（無錫）有限公司 | 癌症治療的療法 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9078440B2 (en) | 2010-12-16 | 2015-07-14 | Bayer Intellectual Property Gmbh | 6-(2-aminophenyl)picolinates and their use as herbicides |
| EP3057970A1 (en) | 2013-10-18 | 2016-08-24 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| US10892525B2 (en) | 2016-06-29 | 2021-01-12 | University Of Kentucky Research Foundation | Rechargeable batteries including high-voltage cathode and redox shuttle conferring overcharge protection |
| JP2019529484A (ja) * | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 |
| JP7327802B2 (ja) * | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| JOP20190272A1 (ar) * | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| EP3710439B1 (en) * | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| ES2969284T3 (es) * | 2018-01-19 | 2024-05-17 | Medshine Discovery Inc | Derivado de piridona-pirimidina que actúa como inhibidor de la muteína krasg12c |
| US20190375749A1 (en) * | 2018-06-11 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| MA51848A (fr) * | 2018-06-12 | 2021-04-21 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| CN113454083A (zh) * | 2019-12-19 | 2021-09-28 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
-
2020
- 2020-12-18 CN CN202080014581.8A patent/CN113454083A/zh active Pending
- 2020-12-18 CN CN202210597916.4A patent/CN115192577B/zh active Active
- 2020-12-18 KR KR1020227024638A patent/KR20220119088A/ko active Pending
- 2020-12-18 TW TW109145045A patent/TWI871397B/zh active
- 2020-12-18 CN CN202111058976.0A patent/CN113651814B/zh active Active
- 2020-12-18 MX MX2022007527A patent/MX2022007527A/es unknown
- 2020-12-18 PE PE2022001137A patent/PE20230161A1/es unknown
- 2020-12-18 CN CN202111617953.9A patent/CN114349750A/zh active Pending
- 2020-12-18 CA CA3165238A patent/CA3165238A1/en active Pending
- 2020-12-18 PH PH1/2022/551503A patent/PH12022551503A1/en unknown
- 2020-12-18 WO PCT/CN2020/137497 patent/WO2021121367A1/en not_active Ceased
- 2020-12-18 AU AU2020404319A patent/AU2020404319A1/en active Pending
- 2020-12-18 CR CR20220351A patent/CR20220351A/es unknown
- 2020-12-18 BR BR112022011421A patent/BR112022011421A2/pt unknown
- 2020-12-18 IL IL293962A patent/IL293962B2/en unknown
- 2020-12-18 JP JP2022537297A patent/JP7644517B2/ja active Active
- 2020-12-18 EP EP20903388.5A patent/EP4077326A4/en active Pending
-
2021
- 2021-03-10 US US17/197,095 patent/US11180506B2/en active Active
- 2021-08-20 US US17/407,418 patent/US11787811B2/en active Active
- 2021-12-27 US US17/562,492 patent/US12195473B2/en active Active
-
2022
- 2022-06-17 CL CL2022001670A patent/CL2022001670A1/es unknown
- 2022-07-05 ZA ZA2022/07450A patent/ZA202207450B/en unknown
- 2022-07-18 CO CONC2022/0010098A patent/CO2022010098A2/es unknown
- 2022-08-05 ZA ZA2022/08783A patent/ZA202208783B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022010098A2 (es) | Inhibidores de proteínas kras mutantes | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| CO2022003782A2 (es) | Inhibidores de kras g12d | |
| UY39526A (es) | Inhibidores de kras g12d | |
| JOP20220008A1 (ar) | مثبطات parp1 | |
| CL2022000027A1 (es) | Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257). | |
| MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| CL2022001452A1 (es) | Inhibidores de masp-2 y métodos de uso. | |
| CR20130533A (es) | INHIBIDORES POTENTES Y SELECTIVOS DE NAv1.3 y NAv1.7 | |
| MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| CL2021002656A1 (es) | Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso. | |
| CL2022001492A1 (es) | Nuevos inhibidores de braf como rompedores de la paradoja | |
| CL2017002856A1 (es) | Compuestos de tioéter como inhibidores de la nitrificación | |
| CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| JOP20210298A1 (ar) | طرق وتركيبات للوقاية من مرض السكري من النوع الأول | |
| CL2022001353A1 (es) | Inhibidores de egfr | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| MX2025003568A (es) | Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap) | |
| EA202192867A1 (ru) | Составы с пролонгированным высвобождением | |
| MX2022006312A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. |